Innovative Sleep Mask to Treat and Prevent Diabetic Retinopathy

PolyPhotonix and Prevail InfoWorks have formed a strategic partnership to spearhead trials of PolyPhotonix’s new product for diabetic retinopathy, the Noctura 400 Sleep Mask.

There has been an investment of $10m from Prevail Partners. After the Food and Drug Administration clinical study is carried out, the product will become available in the US market.

Diabetic retinopathy can result in blindness for people who suffer from diabetes; the Noctura 400 may be able to fix or reduce the development of this disorder. The cutting-edge technology uses phototherapy while the individual is asleep. The device produces a dim light to lessen the danger of hypoxia and retinal damage.

According to an assessment by the NHS, the sleep mask proved successful for 98% of individuals’ eyes.

CEO of PolyPhotonix, Richard Kirk, explained that the “partnership with Prevail InfoWorks will be an asset to our vital work in tackling diabetic retinopathy worldwide. The investment and the forthcoming FDA trial will help support and develop the evidence base for Noctura 400’s clinical effectiveness. At a time when health services across the globe are struggling to bounce back from the COVID-19 crisis, our sleep mask can be used by patients at home, reducing the pressure on frontline hospital services.”

Chief Executive of Prevail InfoWorks, Jack Houriet, expressed that employees at PolyPhotonix are “making major advances in the treatment of diabetic retinopathy. Early-stage treatments are more urgently required than ever with more than 40% of diabetic patients suffering from diabetic retinopathy.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.